Objective — to investigate the antitumor activity of low-molecular-weight heparins (LMWH) in an animal experiment and in patients with locally advanced cervical cancer (LACC). Material and methods. The investigation was conducted in laboratory animals (50 albino outbred rats with transplantable sarcoma M-1) and in 81 patients with LACC, including 45 patients who received a standard chemoradiotherapy (CRT) cycle (a control group) and 36 patients who used a CRT cycle and LMWH (a study group). Nadroparin was used as a LMWH. Survival rates were studied in the laboratory animals; angiogenic marker levels were determined during experimental radiation treatment and LMWH usage. The indicators of angiogenesis and hemostasis were identified in patients with LACC before and after CRT and when LMWH was administered; and the immediate results of chemoradiation for LACC were defined. Results and conclusion. The survival rates of animals, in which radiation therapy was added with LMWH, were statistically significantly different from those of intact animals (p=0.006) and animals in which only nadroparin was given (p=0.006); however, there were no statistically significant differences from the group, in which radiation therapy was used as monotherapy (p=0.88). Radiotherapy and that in combination with LMWH caused a decrease in the level of growth factors, VEGF and FGF being statistically significant (p<0.05). In the study group, the administration of LMWH did not change clinically significantly the levels of angiogenic markers, proinflammatory cytokines, and hemostatic parameters, compared with the control group, and there was no evidence for the effect of LMWH on the immediate results of treatment.